A Phase 2 interventional study of deucravacitinib in Epidermolysis Bullosa Simplex, Ichthyosis and Genodermatosis, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 2 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Centre Hospitalier Universitaire de Nice · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.
Participants will take treatments and have to use bullets during the study period.
The patient will have 8 visits After Confirmation of inclusion criteria and no exclusion criteria, the study will be explain to the patient after signing the inform consent and be included in the study Treatment Period (Period 1); challenge period This period will be the first treatment period that will occur from 16 weeks. During this period the patient will see the doctor at the hospital, he will perform the study procedures The second period : dechallenge (period 2): All patients stop their treatment for 12 weeks.
The second treatment period - rechallenge (period 3) the patient will take the treatment for a second 16 weeks period At week 44 - End of study
At each visit:
The investigator at each visit compliance to the treatment and adverse events, Measure vital signs and perform clinical examination.
The patient will assess the different questionnaires, for the study and have blood sample
Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS > 50/128.
Exclusion Criteria:
challenge-dechallenge -rechallenge design
Drug: deucravacitinib
treatment by deucravacitinib in two phases of challenge
efficacy of deucravacitinib
number of new blister conting every day
Time frame: week 44
Safety of deucravacitinib treatment
record of adverse events
Time frame: week 44
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epidermolysis Bullosa Simplex
Centre Hospitalier Universitaire de Nice